133 related articles for article (PubMed ID: 17168450)
1. [Erlotinib in the treatment of NSCLC: current and novel prospects from the ASCO 2006].
Longo F; Giovanni M
Tumori; 2006; 92(5):suppl 13-22. PubMed ID: 17168450
[No Abstract] [Full Text] [Related]
2. [TRUST study: general practice relevant data on erlotinib in NSCLC].
Knabl A
Wien Med Wochenschr; 2007; 157(21-22):579-80. PubMed ID: 18157598
[No Abstract] [Full Text] [Related]
3. Network meta-analysis: importance of appropriate trial selection.
Edwards SJ; Borrill J
Value Health; 2010 Aug; 13(5):681-2; author reply 683. PubMed ID: 20345543
[No Abstract] [Full Text] [Related]
4. Smoking history: tumor biology and clinical pharmacokinetic implications in patients with lung cancer.
Gadgeel SM
Clin Lung Cancer; 2006 May; 7(6):369-70. PubMed ID: 16800960
[No Abstract] [Full Text] [Related]
5. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
Pérol M
Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S30-4. PubMed ID: 16719154
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.
Wu YL; Kim JH; Park K; Zaatar A; Klingelschmitt G; Ng C
Lung Cancer; 2012 Aug; 77(2):339-45. PubMed ID: 22494567
[TBL] [Abstract][Full Text] [Related]
7. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
Nakagawa K; Kudoh S; Ohe Y; Johkoh T; Ando M; Yamazaki N; Seki A; Takemoto S; Fukuoka M
J Thorac Oncol; 2012 Aug; 7(8):1296-303. PubMed ID: 22610257
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
10. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.
Clark GM; Zborowski DM; Santabarbara P; Ding K; Whitehead M; Seymour L; Shepherd FA;
Clin Lung Cancer; 2006 May; 7(6):389-94. PubMed ID: 16800964
[TBL] [Abstract][Full Text] [Related]
11. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
12. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Stinchcombe TE; Ramalingam SS
Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
[No Abstract] [Full Text] [Related]
13. Beyond first-line NSCLC therapy: chemotherapy or erlotinib?
Paz-Ares L
Lancet Oncol; 2012 Mar; 13(3):225-7. PubMed ID: 22277836
[No Abstract] [Full Text] [Related]
14. NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
Dillon B; Naidoo B; Knight H; Clark P
Lancet Oncol; 2012 Aug; 13(8):764-5. PubMed ID: 23024988
[No Abstract] [Full Text] [Related]
15. Erlotinib in lung cancer.
Takano T; Ohe Y
N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16240472
[No Abstract] [Full Text] [Related]
16. Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study.
Arrieta O; Martinez-Barrera L; Treviño S; Guzman E; Castillo-Gonzalez P; Rios-Trejo MA; Flores-Estrada D; Téllez E; Gonzalez C; de la Cruz Vargas J; Gonzalez-De la Rosa CH; Hernandez-Pedro N; Morales-Barrera R; De la Garza J
J Thorac Oncol; 2008 Aug; 3(8):887-93. PubMed ID: 18670307
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer.
Yoshioka H; Komuta K; Imamura F; Kudoh S; Seki A; Fukuoka M
Lung Cancer; 2014 Nov; 86(2):201-6. PubMed ID: 25280386
[TBL] [Abstract][Full Text] [Related]
18. Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer.
Xu XH; Su J; Fu XY; Xue F; Huang Q; Li DJ; Lu MQ
Cancer Chemother Pharmacol; 2011 Feb; 67(2):475-9. PubMed ID: 20844881
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib for refractory advanced non-small-cell lung cancer.
Tsurutani J; Ballas M; Steinberg SM; Egilsson V; Dennis PA
Lancet; 2006 Jan; 367(9507):300. PubMed ID: 16443034
[No Abstract] [Full Text] [Related]
20. [Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?].
Brückl WM; Wiest GH; Ficker JH
Pneumologie; 2010 Dec; 64(12):727-35. PubMed ID: 20577948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
